VEGF-Sequestering Hydrogel Microspheres for Blood Product Processing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomaterials lack specificity in regulating vascular endothelial growth factor (VEGF) activity, leading to uncontrolled angiogenesis and aberrant wound healing, as they promiscuously bind multiple growth factors, necessitating a more targeted approach to manage VEGF levels in blood products during clinical procedures.
Innovation Solution
Development of VEGF-sequestering hydrogel microspheres with a tunable degradation rate, functionalized with VEGF receptor 2 (VEGFR2)-mimicking peptides, which selectively bind and remove VEGF from blood products, allowing for intra-operative processing and reduced VEGF activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If fibronectin or heparin is used to bind growth factors, then growth factor binding capacity is improved, but binding specificity deteriorates due to promiscuous binding of multiple growth factors
Solution Approach 1:
The patent applies local quality by incorporating specific VEGF-binding peptide sequences (such as VEGFR2-derived peptides) into the hydrogel microsphere structure at localized positions where growth factor binding occurs. This allows the material to exhibit high specificity for VEGF at the binding sites while maintaining overall hydrogel structure integrity, thereby resolving the contradiction between binding capacity and binding specificity.
Solution Approach 2:
The patent uses composite materials by combining hydrogel polymers with specific VEGF-binding peptide sequences to create a hybrid material system. The hydrogel provides structural framework and binding capacity, while the incorporated VEGF-specific peptides provide selective recognition, thus achieving both high binding capacity and high specificity simultaneously.
2Productivity
If VEGF activity is increased to promote angiogenesis during wound healing, then wound healing speed is improved, but pathological angiogenesis and hemangioma formation worsen
Solution Approach 1:
The patent introduces VEGF-sequestering hydrogel microspheres as an intermediary agent that modulates VEGF activity in the wound environment. These microspheres bind excess VEGF through specific peptide interactions, acting as a buffer that maintains VEGF levels within a therapeutic window - sufficient to promote angiogenesis and wound healing but low enough to prevent pathological angiogenesis and hemangioma formation.
Solution Approach 2:
The patent applies parameter changes by dynamically regulating VEGF concentration in the wound milieu through reversible binding interactions. The hydrogel microspheres adjust local VEGF levels based on environmental conditions, increasing binding capacity when VEGF levels are high (preventing pathology) and allowing release when levels are low (promoting healing), thus optimizing the therapeutic outcome.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microspheres effectively reduce VEGF levels in blood products, modulate endothelial cell behavior, and inhibit angiogenesis, thereby improving wound healing outcomes and reducing pathological conditions associated with aberrant VEGF activity.
Implementation Method 1
contacting a VEGF-sequestering hydrogel microsphere with the blood product, the VEGF-sequestering hydrogel microsphere comprising a polymeric microsphere covalently linked to a VEGF-binding peptide variant derived from vascular endothelial growth factor receptor 2 (VEGFR2)
Data Source
AI summary
Vascular endothelial growth factor VEGF-sequestering hydrogel microspheres that have been prepared to selectively bind VEGF from blood products are disclosed herein. In one particular embodiment, the microspheres bind VEGF as part of an intra-operative process such that the growth factor can be removed from the blood products before the products are used in a clinical procedure.